Market revenue in 2022 | USD 70.3 million |
Market revenue in 2030 | USD 295.6 million |
Growth rate | 19.7% (CAGR from 2022 to 2030) |
Largest segment | Commercial production services |
Fastest growing segment | Pre-clinical & Clinical Services |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pre-clinical & Clinical Services, Commercial Production Services |
Key market players worldwide | Lonza Group Ltd, Boehringer Ingelheim, FUJIFILM Holdings Corp, Merck KGaA, Bruker Corp, Sino Biological, Genscript Biotech Corp Class H, Kaneka Corp, Polyplus-transfection, Trenzyme |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to recombinant proteins manufacturing services market will help companies and investors design strategic landscapes.
Commercial production services was the largest segment with a revenue share of 58.46% in 2022. Horizon Databook has segmented the Canada recombinant proteins manufacturing services market based on pre-clinical & clinical services, commercial production services covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada recombinant proteins manufacturing services market, including forecasts for subscribers. This country databook contains high-level insights into Canada recombinant proteins manufacturing services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account